Abstract 202P
Background
The treatment landscape of metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly over past few years. Following publications of several large-scale randomised controlled trials (RCTs) Abiraterone (AA) and Docetaxel (DOC), in addition to androgen deprivation therapy (ADT) have been approved as first line therapies for high risk and high volume mCSPC respectively. In 2019, the picture is further complicated by positive results from TITAN, ENZAMET and ARCHES studies. Both Apalutamide (APA) and Enzalutamide (EZA) have been shown to be superior to placebo (plus ADT) in mCSPC. However, no head to head comparison has been made for these four drugs in first line treatment. We therefore conducted a network meta-analysis to guide the selection of best first line therapy for mCSPC.
Methods
A systematic review of RCTs of AA-/ADT-/APA-/DOC-/EZA-containing treatment regimens in newly diagnosed patients with mCSPC identified seven RCTs. (STAMPEDE arm C and arm G, CHARRTED, GETUG-AFU 15 and LATITUDE, TITAN, ENZAMET and ARCHES trials). We conducted a network meta-analysis with random-effects model under frequentist framework. The reported hazard ratios for overall survival (OS) and progression-free survival (PFS) were incorporated into the model. We used P score to rank the treatments. Treatments having higher P scores are suggested to be more preferred.
Results
Comparing with ADT alone, the hazard ratio (HR) for OS ranged from 0.62 to 0.77 with a highest P score of 0.85 for AA+ADT. For PFS, the HR ranged between 0.38 to 0.63. P Score is again highest at 0.38 for AA+ADT. As exploratory analyses, we compare the OS and PFS of AA +ADT, ENZ+ADT and APA+ADT against DOC +ADT. For OS, HR for AA+ADT is 0.8 while HR for ENZ+ADT and APA +ADT are not statistically significant. For PFS, HR for both ENZ+ADT and AA+ADT are significant (0.62 and 0.61 respectively). AA+ADT has a higher P score than ENZ (0.84 versus 0.81).
Conclusions
Our findings suggest that AA + ADT appears to be more effective than APA-ADT, DOC + ADT, and ENZ+ADT in reducing the risk of death in men with mCSPC and preventing disease progression. This network meta-analysis provides useful guidance to clinicians in choosing the first line therapy in mCSPC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
Presenter: Filipa Pontes
Session: Poster display session
Resources:
Abstract
305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment
Presenter: Tetsuro Wakasugi
Session: Poster display session
Resources:
Abstract
306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
Presenter: Lin Gui
Session: Poster display session
Resources:
Abstract
307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States
Presenter: Mahmoud KhalafAllah
Session: Poster display session
Resources:
Abstract
308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study
Presenter: Yi-Fang Huang
Session: Poster display session
Resources:
Abstract
309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
Presenter: Ai Horinouchi
Session: Poster display session
Resources:
Abstract
310P - Laser and PDT for the oral leukoplakia
Presenter: Sadykov Rasul
Session: Poster display session
Resources:
Abstract
311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital
Presenter: Priscilla Caguioa
Session: Poster display session
Resources:
Abstract
312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence
Presenter: Shanavas Palliyal
Session: Poster display session
Resources:
Abstract
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract